Nasdaq:ALT Archives

Nasdaq:ALT
US02155H1014

January 29, 2026

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced…

By sf-admin